New Zealand markets open in 3 hours 47 minutes
  • NZX 50

    12,090.93
    +123.21 (+1.03%)
     
  • NZD/USD

    0.6436
    +0.0004 (+0.06%)
     
  • ALL ORDS

    7,709.70
    +23.60 (+0.31%)
     
  • OIL

    76.99
    -1.88 (-2.38%)
     
  • GOLD

    1,938.60
    -6.70 (-0.34%)
     

Investing in Pharming Group (AMS:PHARM) a year ago would have delivered you a 59% gain

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost returns by picking market-beating companies to own shares in. For example, the Pharming Group N.V. (AMS:PHARM) share price is up 59% in the last 1 year, clearly besting the market decline of around 15% (not including dividends). So that should have shareholders smiling. Zooming out, the stock is actually down 18% in the last three years.

Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.

View our latest analysis for Pharming Group

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

During the last year Pharming Group grew its earnings per share (EPS) by 33%. The share price gain of 59% certainly outpaced the EPS growth. This indicates that the market is now more optimistic about the stock.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

earnings-per-share-growth
earnings-per-share-growth

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. It might be well worthwhile taking a look at our free report on Pharming Group's earnings, revenue and cash flow.

A Different Perspective

We're pleased to report that Pharming Group shareholders have received a total shareholder return of 59% over one year. There's no doubt those recent returns are much better than the TSR loss of 1.5% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Pharming Group you should know about.

Pharming Group is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on NL exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here